Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carc...
Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
About this item
Full title
Author / Creator
Publisher
Australia: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Australia: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and hyperglycemia. However, there are no reports on...
Alternative Titles
Full title
Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5e29a65451b64a51a435a67d2bf73a9d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5e29a65451b64a51a435a67d2bf73a9d
Other Identifiers
ISSN
2577-171X
E-ISSN
2577-171X
DOI
10.1002/iju5.12734
